Ann Lindstrand1, Rutger Bennet2, Ilias Galanis3, Margareta Blennow4, Lina Schollin Ask5, Sofia Hultman Dennison6, Malin Ryd Rinder5, Margareta Eriksson2, Birgitta Henriques-Normark7, Ake Ortqvist8, Tobias Alfvén9. 1. Public Health Agency of Sweden, Solna, Sweden; Departments of Public Health Sciences, Division of Global Health, ann.lindstrand@folkhalsomyndigheten.se. 2. Astrid Lindgren Children's Hospital, and. 3. Public Health Agency of Sweden, Solna, Sweden; 4. Sachs' Children and Youth Hospital, South General Hospital, Stockholm, Sweden; Clinical Sciences and Education, and. 5. Sachs' Children and Youth Hospital, South General Hospital, Stockholm, Sweden; 6. Department of Otorhinolaryngology, Karolinska University Hospital, Stockholm, Sweden; 7. Public Health Agency of Sweden, Solna, Sweden; Microbiology, Tumor and Cell Biology, Karolinska Institutet, Stockholm, Sweden; Department of Laboratory Medicine, Division of Clinical Microbiology, Karolinska University Hospital, Solna, Sweden; 8. Department of Communicable Disease Control and Prevention, Stockholm County Council, Sweden; and Department of Medicine, Unit of Infectious Diseases, Karolinska Institutet, Karolinska, Solna, Sweden. 9. Departments of Public Health Sciences, Division of Global Health, Sachs' Children and Youth Hospital, South General Hospital, Stockholm, Sweden;
Abstract
BACKGROUND AND OBJECTIVE: Streptococcus pneumoniae is a major cause of pneumonia and sinusitis. Pneumonia kills >1 million children annually, and sinusitis is a potentially serious pediatric disease that increases the risk of orbital and intracranial complications. Although pneumococcal conjugate vaccine (PCV) is effective against invasive pneumococcal disease, its effectiveness against pneumonia is less consistent, and its effect on sinusitis is not known. We compared hospitalization rates due to sinusitis, pneumonia, and empyema before and after sequential introduction of PCV7 and PCV13. METHOD: All children 0 to <18 years old hospitalized for sinusitis, pneumonia, or empyema in Stockholm County, Sweden, from 2003 to 2012 were included in a population-based study of hospital registry data on hospitalizations due to sinusitis, pneumonia, or empyema. Trend analysis, incidence rates, and rate ratios (RRs) were calculated comparing July 2003 to June 2007 with July 2008 to June 2012, excluding the year of PCV7 introduction. RESULTS: Hospitalizations for sinusitis decreased significantly in children aged 0 to <2 years, from 70 to 24 cases per 100 000 population (RR = 0.34, P < .001). Hospitalizations for pneumonia decreased significantly in children aged 0 to <2 years, from 450 to 366 per 100 000 population (RR = 0.81, P < .001) and in those aged 2 to <5 years from 250 to 212 per 100 000 population (RR = 0.85, P = .002). Hospitalization for empyema increased nonsignificantly. Trend analyses showed increasing hospitalization for pneumonia in children 0 to <2 years before intervention and confirmed a decrease in hospitalizations for sinusitis and pneumonia in children aged 0 to <5 years after intervention. CONCLUSIONS: PCV7 and PCV13 vaccination led to a 66% lower risk of hospitalization for sinusitis and 19% lower risk of hospitalization for pneumonia in children aged 0 to <2 years, in a comparison of 4 years before and 4 years after vaccine introduction.
BACKGROUND AND OBJECTIVE:Streptococcus pneumoniae is a major cause of pneumonia and sinusitis. Pneumonia kills >1 million children annually, and sinusitis is a potentially serious pediatric disease that increases the risk of orbital and intracranial complications. Although pneumococcal conjugate vaccine (PCV) is effective against invasive pneumococcal disease, its effectiveness against pneumonia is less consistent, and its effect on sinusitis is not known. We compared hospitalization rates due to sinusitis, pneumonia, and empyema before and after sequential introduction of PCV7 and PCV13. METHOD: All children 0 to <18 years old hospitalized for sinusitis, pneumonia, or empyema in Stockholm County, Sweden, from 2003 to 2012 were included in a population-based study of hospital registry data on hospitalizations due to sinusitis, pneumonia, or empyema. Trend analysis, incidence rates, and rate ratios (RRs) were calculated comparing July 2003 to June 2007 with July 2008 to June 2012, excluding the year of PCV7 introduction. RESULTS: Hospitalizations for sinusitis decreased significantly in children aged 0 to <2 years, from 70 to 24 cases per 100 000 population (RR = 0.34, P < .001). Hospitalizations for pneumonia decreased significantly in children aged 0 to <2 years, from 450 to 366 per 100 000 population (RR = 0.81, P < .001) and in those aged 2 to <5 years from 250 to 212 per 100 000 population (RR = 0.85, P = .002). Hospitalization for empyema increased nonsignificantly. Trend analyses showed increasing hospitalization for pneumonia in children 0 to <2 years before intervention and confirmed a decrease in hospitalizations for sinusitis and pneumonia in children aged 0 to <5 years after intervention. CONCLUSIONS: PCV7 and PCV13 vaccination led to a 66% lower risk of hospitalization for sinusitis and 19% lower risk of hospitalization for pneumonia in children aged 0 to <2 years, in a comparison of 4 years before and 4 years after vaccine introduction.
Authors: Javier de-Miguel-Díez; Ana López-de-Andrés; Valentín Hernández-Barrera; José M de-Miguel-Yanes; David Carabantes-Alarcón; Zichen Ji; Jose J Zamorano-Leon; Rodrigo Jiménez-García Journal: Eur J Pediatr Date: 2022-04-25 Impact factor: 3.860
Authors: Thomas Cars; Irene Eriksson; Anna Granath; Björn Wettermark; Jenny Hellman; Christer Norman; Anders Ternhag Journal: BMJ Open Date: 2017-11-15 Impact factor: 2.692
Authors: Grant A Mackenzie; Philip C Hill; Shah M Sahito; David J Jeffries; Ilias Hossain; Christian Bottomley; Uchendu Uchendu; David Ameh; Malick Ndiaye; Chidebereh D Osuorah; Oyedeji Adeyemi; Jayani Pathirana; Yekini Olatunji; Bade Abatan; Ebirim Ahameefula; Bilquees S Muhammad; Augustin E Fombah; Debasish Saha; Roslyn Mackenzie; Ian Plumb; Aliu Akano; Bernard Ebruke; Readon C Ideh; Bankole Kuti; Peter Githua; Emmanuel Olutunde; Ogochukwu Ofordile; Edward Green; Effua Usuf; Henry Badji; Usman N A Ikumapayi; Ahmad Manjang; Rasheed Salaudeen; E David Nsekpong; Sheikh Jarju; Martin Antonio; Sana Sambou; Lamin Ceesay; Yamundow Lowe-Jallow; Dawda Sowe; Momodou Jasseh; Kim Mulholland; Maria Knoll; Orin S Levine; Stephen R Howie; Richard A Adegbola; Brian M Greenwood; Tumani Corrah Journal: Lancet Infect Dis Date: 2017-06-07 Impact factor: 25.071